Computer-aided structural modeling and drug discovery for G-protein-coupled receptors in the age of artificial intelligence G-protein-coupled receptors (GPCRs) are a large family of membrane proteins that mediate cellular responses to diverse stimuli and serve as targets fo…

Nice read: a mini-review by Novack & Filizola on #AI in #GPCR #DrugDiscovery.
Summarizes well where AI is actually helping and where it is not yet reliable. Current main limitations: active states, flexible regions, transient interfaces, and interpretability.
www.sciencedirect.com/science/arti...

🌟 ハッシュタグ 🌟
#ニュース #時事 #政治 #生活 #カーリング #科学 #火災 #富津市 #東京科学大学 #創薬 #GPCR #アデノシン受容体 #ロコソラーレ #予選リーグ突破

Welsh firm Antiverse raises funds for AI antibody platform Cardiff's Antiverse has raised $9.3m to develop its AI-based design platform for antibodies against hard-to-reach targets like GPCRs and ion channels.

#Antiverse #AI #AIantibodyplatform #biotech #drugdiscoveryprogrammes #antibodybasedtherapeutics #antibodies #drugtargets #Gproteincoupledreceptors #GPCR #ionchannels #NxeraPharma #GPCRs #cellularcommunication #transmembraneprotein #Tcellreceptor #TCR #antiPD1antibodies #drugdiscovery
zurl.co/cAKcg

New developments in #GPCR assay technologies now enable faster and more precise discovery of therapeutics across #oncology, #immunology, pain and #inflammatory disorders. See how we can support your drug and antibody development

🔗https://tinyurl.com/ytnp3hk4

#antibodies #proteins #lifesciences

Structure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights Structure Therapeutics (NASDAQ: GPCR) reported positive Phase 2 aleniglipron results, including a placebo-adjusted 15.3% weight loss at 36 weeks (240 mg) and no observed weight-loss plateau. The company holds $1.4 billion in cash and short-term investments, expected to fund operations through end-2028.Topline ACCESS II 44-week results are expected in Q1 2026 and a Phase 3 program is planned to start in 2H 2026; ACCG-2671 entered Phase 1 with data due 2H 2026.

#GPCR Structure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights

www.stocktitan.net/news/GPCR/structure-ther...

5 Grant-Writing Tips from the GPCR Lab What if you approached grant writing like a GPCR signalling pathway? Professor Stuart Maudsley shares five tips for writing grants that cut through noise and capture reviewer attention.

What if you approached grant-writing like a GPCR signaling pathway? 🤔

In this new guest blog, Professor Stuart Maudsley of @moffittnews.bsky.social shares five practical tips for capturing reviewer attention - with some smart analogies! 🔬

Read the article: ow.ly/Ragi50Yi1IY

#GPCR #grantwriting

Exploring the Thermodynamic Properties of Doxepin Isomers at H1 Receptor Binding This research uncovers the thermodynamic interactions of doxepin isomers at the histamine H1 receptor, unveiling implications for drug design and personalized medicine.

Exploring the Thermodynamic Properties of Doxepin Isomers at H1 Receptor Binding #Japan #Tokyo #GPCR #doxepin #H1_receptor

Congratulations to Sara Abusara of @uniofaberdeen.bsky.social who was the winner of our prize draw at the Endocrine Metabolic GPCRs 2026 meeting in Liverpool, UK! 🎉

We loved meeting so many great life scientists this week and we look forward to seeing you all again next year! 👋

#endocrine #gpcr

If you're at the Endocrine Metabolic GPCRs 2026 meeting in Liverpool, UK, this week, why not say 'hello' to Hello Bio! 👋

You'll find James in the exhibition space today and tomorrow - he looks forward to meeting you 😊

#endocrine #endocrinemetabolic #gpcr #GPCRs #endocrinology #metabolism

Antibody Therapeutics(IF=4.5, Oxford University Press)
📢📢Call for Proposals: GPCR-Targeting Antibodies 🧬
Covering discovery, engineering, structure, AI design & translational studies.
🗓 Proposal deadline: Feb 28, 2026
#AntibodyTherapeutics #GPCR #Biologics

Frontiers | Rational Design of Peptide-Based Therapeutics for GPCRs G protein–coupled receptors (GPCRs) are the largest family of membrane proteins and key regulators of physiological processes such as metabolism, immunity, s...

📢 Call for papers | @FrontiersIn

"Rational Design of Peptide-Based Therapeutics for GPCRs"

We invite original research, reviews & perspectives — from #peptidechemistry and #GPCR biology to #DrugDiscovery.

#Peptides #peptide-conjugates #Peptidomimetics

www.frontiersin.org/research-top...

Unlock deeper insights in GPCR research using Promega’s bioluminescence-based assays.

Measure each step of the signalling cascade with ease.

More info at: www.promega.co.uk/applications/small-molec...

#GPCR #Assays #bioluminescence

Just In: ( NASDAQ: #GPCR ) GPCR Price Target Alert: $102.00. Issued by Goldman Sachs

ヒスタミンH3受容体の活性を増幅するアミノ酸変異の発見と意義 東京理科大学の研究グループが、ヒスタミンH3受容体の恒常的活性を増強する4つのアミノ酸変異を特定しました。特に神経疾患治療に向けた新たなステップとして注目されています。

ヒスタミンH3受容体の活性を増幅するアミノ酸変異の発見と意義 #ヒスタミンH3受容体 #GPCR #神経疾患

東京理科大学の研究グループが、ヒスタミンH3受容体の恒常的活性を増強する4つのアミノ酸変異を特定しました。特に神経疾患治療に向けた新たなステップとして注目されています。

A 10% Owner Of Structure Therapeutics Shed Shares | The Motley Fool A company controlled by the Johnson family sold thousands of shares of this clinical-stage biopharmaceutical company, but that hasn't stopped the pharmaceutical stock from surging.

#GPCR #a976e66e-b965-447f-a7d8-93f7a0a2f3a4 #coveragefilings #Health #Care

Origin | Interest | Match

Just In: ( NASDAQ: #GPCR ) Can This Stock Double Again in 2026?

Dynamics of Ligand Binding Sites and Chloride Penetration in a Bitter Taste GPCR
Niv, M. Y. et al.
Paper
Details
#GPCR #LigandBinding #ChloridePenetration

📢📢
The last #GPCR Zoominar of 2025 is a CaféSession with Prof. Graeme Milligan from the #UniversityOfGlasgow. You will discover the fascinating scientific path of Prof. #Milligan and will have the chance to engage with him on career-related topics.

Link: www.gpcrforum.org/events/gpcr-...

Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity Structure Therapeutics (NASDAQ: GPCR) initiated a first-in-human Phase 1 study of ACCG-2671, an oral once-daily small molecule amylin receptor agonist for the treatment of obesity, on Dec. 17, 2025. ACCG-2671 was designed with the company’s structure-based GPCR drug discovery platform.Preclinical data reported include potent target engagement, robust weight loss as monotherapy, additional weight loss in combination with a GLP-1 receptor agonist, favorable safety, and PK supporting once-daily dosing. The Phase 1 trial will assess safety, tolerability, pharmacokinetics and pharmacodynamics in healthy volunteers and people with obesity using single-ascending and multiple-ascending dose cohorts.

#GPCR Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity

www.stocktitan.net/news/GPCR/structure-ther...

Structure Therapeutics (GPCR) Stock Momentum Breakout Story - FFR Trading GPCR stock analysis: Structure Therapeutics momentum breakout on strong GLP-1 trial results and bullish forecasts. .

GPCR triples. Analysts see more upside.
VKTX heating up too.
Biotech traders: you’ll want to read this one.
zurl.co/HiCYT
#GPCR #Markets #Biotech

⚙️ Using long-timescale molecular dynamics (#MD), ensemble analysis & #GPCR transmission-switch reasoning, we explain a clinically relevant selectivity and safety phenotype.

BREAKING NEWS: ( NASDAQ: #GPCR ) Overweight Recommendation Issued On GPCR By Morgan Stanley

Structure Therapeutics Announces Pricing of Upsized $650 Million Public Offering of ADSs and Pre-Funded Warrants Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced the pricing of its upsized underwritten

#GPCR Structure Therapeutics Announces Pricing of Upsized $650 Million Public Offering of ADSs and Pre-Funded Warrants

www.stocktitan.net/news/GPCR/structure-ther...

Structure stock soars after aleniglipron shows strong weight-loss in Phase II obesity study Structure Therapeutics (GPCR) announced that aleniglipron — its once-daily, oral small-molecule GLP-1 receptor agonist — produced robust weight loss in its

Structure #GPCR stock soars after aleniglipron shows strong weight-loss in Phase II obesity study
prismmarketview.com/structure-st...

🧬 New VESS talk alert! "Understanding GPCRs with massive mutagenesis" with Taylor Mighell @crg.eu @sangerinstitute.bsky.social @embo.org @cam.ac.uk
Watch the Dec 2 seminar now on YouTube
#VariantEffects #GPCR #FunctionalGenomics
🎥 www.youtube.com/watch?v=lSFt...

Excited to share #Intracellular and Dual-Site #Inhibition of a #bitter #taste #GPCR. Congrats Nitsan Dallal and team!

#GPCR #WVE #ef0a245f-cbb3-4e88-bdd9-83239da31423 #investing #Health #Care

Origin | Interest | Match

Most Searched, Monday December 8, 2025 – Crystal Equity Research

Most searched small-cap stocks, Mon Dec 8th - #GPCR #FSLY #ABTC #TWG #JBLU #FULC #NVTS #DNN #OCUL #IRBT #BITF #PLUG #CETX #WVE #UUUU #USAR #PHR #ONDS #IDR #BBAI - More: crystalequityresearch.com/most-searche... - #smallcap

Structure Therapeutics Announces Proposed $500 Million Public Offering of American Depositary Shares and Pre-Funded Warrants Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced the commencement of a proposed

#GPCR Structure Therapeutics Announces Proposed $500 Million Public Offering of American Depositary Shares and Pre-Funded Warrants

www.stocktitan.net/news/GPCR/structure-ther...

📢 Stocks Trending NOW: #CFLT #CETX #TGL #CVNA #AVGO #CRWV #MRVL #WVE #IBM #GPCR